Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-COVID: Intermediate vs Prophylactic Anticoagulation in Severe COVID-19
NCT04367831Phase 4Completed
- Sponsor
- Columbia University
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin and heparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Columbia University. Primary endpoint: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU. Started May 2020; status: completed.
02
Drugs
enoxaparinheparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04367831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367831.